CQP 201‐403 in Parkinson's disease: An open‐label pilot study

Ronald F. Pfeiffer; Leonel H. Herrera; Carolyn S. Glaeske; Ruth E. Hofman

doi:10.1002/mds.870040310

CQP 201‐403 in Parkinson's disease: An open‐label pilot study

Ronald F. Pfeiffer, Leonel H. Herrera, Carolyn S. Glaeske, Ruth E. Hofman

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.

Original language	English (US)
Pages (from-to)	278-281
Number of pages	4
Journal	Movement Disorders
Volume	4
Issue number	3
DOIs	https://doi.org/10.1002/mds.870040310
State	Published - 1989
Externally published	Yes

Keywords

CQP 201‐403
Dopamine agonist
Parkinson's disease

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/mds.870040310

Cite this

@article{930f9aec5112434bbad94e51adf6a180,

title = "CQP 201‐403 in Parkinson's disease: An open‐label pilot study",

abstract = "The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.",

keywords = "CQP 201‐403, Dopamine agonist, Parkinson's disease",

author = "Pfeiffer, {Ronald F.} and Herrera, {Leonel H.} and Glaeske, {Carolyn S.} and Hofman, {Ruth E.}",

year = "1989",

doi = "10.1002/mds.870040310",

language = "English (US)",

volume = "4",

pages = "278--281",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - CQP 201‐403 in Parkinson's disease

T2 - An open‐label pilot study

AU - Pfeiffer, Ronald F.

AU - Herrera, Leonel H.

AU - Glaeske, Carolyn S.

AU - Hofman, Ruth E.

PY - 1989

Y1 - 1989

N2 - The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.

AB - The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.

KW - CQP 201‐403

KW - Dopamine agonist

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0024403765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024403765&partnerID=8YFLogxK

U2 - 10.1002/mds.870040310

DO - 10.1002/mds.870040310

M3 - Article

C2 - 2571083

AN - SCOPUS:0024403765

SN - 0885-3185

VL - 4

SP - 278

EP - 281

JO - Movement Disorders

JF - Movement Disorders

IS - 3

ER -

CQP 201‐403 in Parkinson's disease: An open‐label pilot study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this